Skip to main content

Mitral Regurgitation Functional

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Nyra Medical
Nyra MedicalGA - Atlanta
1 program
CARLEN SystemN/A1 trial
Active Trials
NCT07503236Not Yet Recruiting30Est. Dec 2032
Boston Scientific
Boston ScientificCA - Valencia
1 program
Millipede Transcatheter Annuloplasty Ring SystemN/A1 trial
Active Trials
NCT04147884Active Not Recruiting4Est. Nov 2026
Abbott
AbbottABBOTT PARK, IL
1 program
MitraClip implantationN/A1 trial
Active Trials
NCT03503851Withdrawn0Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Nyra MedicalCARLEN System
Boston ScientificMillipede Transcatheter Annuloplasty Ring System
AbbottMitraClip implantation

Clinical Trials (3)

Total enrollment: 34 patients across 3 trials

NCT07503236Nyra MedicalCARLEN System

Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System

Start: Jun 2026Est. completion: Dec 203230 patients
N/ANot Yet Recruiting
NCT04147884Boston ScientificMillipede Transcatheter Annuloplasty Ring System

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Start: Nov 2019Est. completion: Nov 20264 patients
N/AActive Not Recruiting
NCT03503851AbbottMitraClip implantation

Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation

Start: May 2018Est. completion: Dec 20200
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.